{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=FSH+Muscular+Dystrophy&page=2",
    "query": {
      "condition": "FSH Muscular Dystrophy",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=FSH+Muscular+Dystrophy&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-07-22T08:39:05.990Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07086521",
      "title": "Safety and Preliminary Efficacy of ULSC in Facioscapulohumeral Muscular Dystrophy (FSHD)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "FSHD - Facioscapulohumeral Muscular Dystrophy"
      ],
      "interventions": [
        {
          "name": "ULSC",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Restem, LLC.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "15 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2025-12-01",
      "completion_date": "2029-03",
      "has_results": false,
      "last_update_posted_date": "2025-12-08",
      "last_synced_at": "2026-07-22T08:39:05.990Z",
      "location_count": 1,
      "location_summary": "Palo Alto, California",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07086521"
    },
    {
      "nct_id": "NCT04264442",
      "title": "Efficacy and Safety of Losmapimod in Treating Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD) With Open-Label Extension (OLE)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Facioscapulohumeral Muscular Dystrophy (FSHD)"
      ],
      "interventions": [
        {
          "name": "Losmapimod",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Fulcrum Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 76,
      "start_date": "2020-02-13",
      "completion_date": "2024-11-07",
      "has_results": true,
      "last_update_posted_date": "2025-09-30",
      "last_synced_at": "2026-07-22T08:39:05.990Z",
      "location_count": 12,
      "location_summary": "Irvine, California • Los Angeles, California • Gainesville, Florida + 9 more",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04264442"
    },
    {
      "nct_id": "NCT00027391",
      "title": "Study of Albuterol and Oxandrolone in Patients With Facioscapulohumeral Dystrophy (FSHD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Muscular Dystrophies"
      ],
      "interventions": [
        {
          "name": "Albuterol",
          "type": "DRUG"
        },
        {
          "name": "Oxandrolone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "FDA Office of Orphan Products Development",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 160,
      "start_date": "2001-09",
      "completion_date": "2004-08",
      "has_results": false,
      "last_update_posted_date": "2015-03-25",
      "last_synced_at": "2026-07-22T08:39:05.990Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00027391"
    },
    {
      "nct_id": "NCT01437345",
      "title": "A Multicenter Collaborative Study on the Clinical Features, Expression Profiling, and Quality of Life of Infantile Onset FSHD",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Facioscapulohumeral Muscular Dystrophy"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Cooperative International Neuromuscular Research Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 53,
      "start_date": "2012-07",
      "completion_date": "2017-08",
      "has_results": false,
      "last_update_posted_date": "2017-10-11",
      "last_synced_at": "2026-07-22T08:39:05.990Z",
      "location_count": 7,
      "location_summary": "Sacramento, California • Washington D.C., District of Columbia • Minneapolis, Minnesota + 4 more",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Charlotte",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01437345"
    },
    {
      "nct_id": "NCT00104078",
      "title": "Study Evaluating MYO-029 in Adult Muscular Dystrophy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Becker Muscular Dystrophy",
        "Facioscapulohumeral Muscular Dystrophy",
        "Limb-Girdle Muscular Dystrophy"
      ],
      "interventions": [
        {
          "name": "MYO-029",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Wyeth is now a wholly owned subsidiary of Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 108,
      "start_date": "2005-02",
      "completion_date": "2007-01",
      "has_results": false,
      "last_update_posted_date": "2007-12-28",
      "last_synced_at": "2026-07-22T08:39:05.990Z",
      "location_count": 9,
      "location_summary": "Washington D.C., District of Columbia • Kansas City, Kansas • Baltimore, Maryland + 6 more",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00104078"
    },
    {
      "nct_id": "NCT03943290",
      "title": "Extension Study to Evaluate the Long-Term Effects of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy (FSHD) and Charcot-Marie Tooth (CMT) Disease Types 1 and X (CMT1 and CMTX)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Facioscapulohumeral Muscular Dystrophy",
        "Charcot-Marie-Tooth Disease"
      ],
      "interventions": [
        {
          "name": "ACE-083",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 62,
      "start_date": "2019-05-10",
      "completion_date": "2020-03-11",
      "has_results": true,
      "last_update_posted_date": "2022-09-26",
      "last_synced_at": "2026-07-22T08:39:05.990Z",
      "location_count": 19,
      "location_summary": "Orange, California • Sacramento, California • Aurora, Colorado + 16 more",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03943290"
    },
    {
      "nct_id": "NCT02836418",
      "title": "Study to Evaluate the Long-Term Safety, Tolerability, and Biological Activity of ATYR1940 in Participants With Limb Girdle and Facioscapulohumeral Muscular Dystrophy (FSHD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Facioscapulohumeral Muscular Dystrophy",
        "Limb Girdle Muscular Dystrophy"
      ],
      "interventions": [
        {
          "name": "ATYR1940",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "aTyr Pharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "16 Years to 25 Years"
      },
      "enrollment_count": 8,
      "start_date": "2016-07-13",
      "completion_date": "2017-04-18",
      "has_results": true,
      "last_update_posted_date": "2023-12-22",
      "last_synced_at": "2026-07-22T08:39:05.990Z",
      "location_count": 3,
      "location_summary": "Irvine, California • Stanford, California • Salt Lake City, Utah",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02836418"
    },
    {
      "nct_id": "NCT06547216",
      "title": "Phase 2 Open-label Extension Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "FSHD",
        "FSHD1",
        "FSHD2",
        "FMD",
        "FMD2",
        "Fascioscapulohumeral Muscular Dystrophy",
        "Fascioscapulohumeral Muscular Dystrophy Type 1",
        "Fascioscapulohumeral Muscular Dystrophy Type 2",
        "Dystrophies, Facioscapulohumeral Muscular",
        "Dystrophy, Facioscapulohumeral Muscular",
        "Facioscapulohumeral Muscular Dystrophy 1",
        "Facioscapulohumeral Muscular Dystrophy 2",
        "Facio-Scapulo-Humeral Dystrophy",
        "Atrophy, Facioscapulohumeral",
        "Atrophies, Facioscapulohumeral",
        "Facioscapulohumeral Atrophy",
        "Muscular Dystrophies",
        "Muscular Dystrophy, Facioscapulohumeral",
        "FSH Muscular Dystrophy",
        "Landouzy Dejerine Dystrophy",
        "Landouzy-Dejerine Muscular Dystrophy",
        "Dystrophies, Landouzy-Dejerine",
        "Dystrophy, Landouzy-Dejerine",
        "Landouzy-Dejerine Syndrome",
        "Muscular Dystrophy, Landouzy Dejerine",
        "Progressive Muscular Dystrophy",
        "FSH"
      ],
      "interventions": [
        {
          "name": "AOC 1020",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Avidity Biosciences, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "72 Years",
        "sex": "ALL",
        "summary": "16 Years to 72 Years"
      },
      "enrollment_count": 84,
      "start_date": "2024-07-25",
      "completion_date": "2030-06",
      "has_results": false,
      "last_update_posted_date": "2026-07-14",
      "last_synced_at": "2026-07-22T08:39:05.990Z",
      "location_count": 14,
      "location_summary": "Los Angeles, California • Palo Alto, California • San Diego, California + 11 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06547216"
    },
    {
      "nct_id": "NCT02927080",
      "title": "Study of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy (FSHD)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Facioscapulohumeral Muscular Dystrophy"
      ],
      "interventions": [
        {
          "name": "ACE-083",
          "type": "DRUG"
        },
        {
          "name": "ACE-083 or placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 95,
      "start_date": "2016-11",
      "completion_date": "2019-10-09",
      "has_results": true,
      "last_update_posted_date": "2022-09-26",
      "last_synced_at": "2026-07-22T08:39:05.990Z",
      "location_count": 18,
      "location_summary": "Los Angeles, California • Sacramento, California • Aurora, Colorado + 15 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02927080"
    },
    {
      "nct_id": "NCT02766985",
      "title": "Rasch-analysis of Clinical Severity in FSHD",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Facioscapulohumeral Muscular Dystrophy"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University of Kansas Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 44,
      "start_date": "2016-03",
      "completion_date": "2017-04-18",
      "has_results": false,
      "last_update_posted_date": "2018-04-12",
      "last_synced_at": "2026-07-22T08:39:05.990Z",
      "location_count": 2,
      "location_summary": "Kansas City, Kansas • Salt Lake City, Utah",
      "locations": [
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02766985"
    }
  ]
}